Monitoring misuse and abuse of psychoactive substances in France: Insights from substance abuse treatment facilities through the OPPIDUM program
Clémence Lacroix(Inserm), Joëlle Micallef(Assistance Publique Hôpitaux de Marseille), Élisabeth Frauger(Inserm), Hélène Peyrière(Centre Hospitalier Universitaire de Montpellier), Élisabeth Jouve(Inserm)
Cited by 11
Related Papers
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database
|Journal of the Neurological Sciences|2019|60
Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
|Clinical Pharmacology & Therapeutics|2021|48
Non-targeted screening for novel psychoactive substances among agitated emergency department patients
|Clinical Toxicology|2016|42
Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients’ view?
|Revue Neurologique|2023|32